Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773228 | 0.84 | NLRP3 (0.82) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL4767657 | 0.81 | NLRP3 (0.69) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL4771934 | 0.81 | L3MBTL1 (0.61) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL514620 | 0.80 | GAA (0.67) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL4773984 | 0.79 | NLRP3 (0.66) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL31435118 | 0.78 | NLRP3 (1.00) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL20702997 | 0.78 | NLRP3 (1.00) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL11123318 | 0.78 | SMN1; SMN2 (0.61) | ALDH1A1TSHRMAOBKDM4EHTT | |
| SCHEMBL11852070 | 0.77 | NLRP3 (0.60) | NLRP3L3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL20302610 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TSHRMAOBKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | PARK7, GLS, IAPP | NLRP3 547/4885L3MBTL1 2626/4885GAA 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.